KalVista Pharmaceuticals Inc. (NASDAQ: KALV) is -59.86% lower on its value in year-to-date trading and has touched a low of $4.12 and a high of $17.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KALV stock was last observed hovering at around $5.26 in the last trading session, with the day’s gains setting it 0.05% off its average median price target of $22.00 for the next 12 months. It is also 82.3% off the consensus price target high of $30.00 offered by 6 analysts, but current levels are 62.07% higher than the price target low of $14.00 for the same period.
Currently trading at $5.31, the stock is 1.63% and -30.04% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.23 million and changing 0.95% at the moment leaves the stock -54.82% off its SMA200. KALV registered -66.79% loss for a year compared to 6-month loss of -37.68%.
The stock witnessed a 17.74% gain in the last 1 month and extending the period to 3 months gives it a -67.97%, and is -0.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.44% over the week and 7.06% over the month.
Distance from 52-week low is 28.88% and -69.39% from its 52-week high.
KalVista Pharmaceuticals Inc. (KALV) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for KalVista Pharmaceuticals Inc. (KALV) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
KalVista Pharmaceuticals Inc. is expected to release its quarterly report on 03/09/2023.The EPS is expected to shrink by -38.90% this year
KalVista Pharmaceuticals Inc. (KALV) Top Institutional Holders
The shares outstanding are 24.56M, and float is at 23.98M with Short Float at 9.49%.
KalVista Pharmaceuticals Inc. (KALV) Insider Activity
A total of 12 insider transactions have happened at KalVista Pharmaceuticals Inc. (KALV) in the last six months, with sales accounting for 7 and purchases happening 5 times. The most recent transaction is an insider sale by Yea Christopher, the company’s Chief Development Officer. SEC filings show that Yea Christopher sold 1,139 shares of the company’s common stock on Nov 18 at a price of $5.44 per share for a total of $6196.0. Following the sale, the insider now owns 34232.0 shares.
KalVista Pharmaceuticals Inc. disclosed in a document filed with the SEC on Nov 18 that Palleiko Benjamin L (CFO, CBO & Secretary) sold a total of 722 shares of the company’s common stock. The trade occurred on Nov 18 and was made at $5.44 per share for $3928.0. Following the transaction, the insider now directly holds 68390.0 shares of the KALV stock.
Still, SEC filings show that on Nov 18, Feener Edward P. (Chief Scientific Officer) disposed off 530 shares at an average price of $5.44 for $2883.0. The insider now directly holds 62,376 shares of KalVista Pharmaceuticals Inc. (KALV).